«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:

22卷

期数:

2016年02期

页码:

140-143

栏目:

临床医学

出版日期:

2016-03-20

文章信息/Info

Title:

Diagnostic implication of TuM2-PK, tPSA, fPSA/tPSA ratio and PSAD for prostate cancer in PSA gray area

文章编号:

1006-8147（2016）02-0140-04

作者:

管明秀¹; 2; 周云丽¹; 王 萌¹; 仝颖娜¹; 刘晓彬¹

（1．天津医科大学肿瘤医院检验科，国家肿瘤临床医学研究中心，天津市“肿瘤防治”重点实验室，天津300060；2.天津市宝坻区人民医院检验科，天津医科大学宝坻临床学院，天津301800）

Author(s):

GUAN Ming-xiu¹; 2;  ZHOU Yun-li¹;  WANG-Meng¹; TONG Ying-na¹;  LIU Xiao-bin¹

(1.Department of Clinical Laboratory, Cancer Institute and Hospital, Tianjin Medical University, National Clinical Research Center of Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China； 2.Department of Clinical Laboratory, Tianjin Baodi Hospital, Baodi Clinical College ，Tianjin Medical University, Tianjin 301800, China)

关键词:

前列腺癌; 前列腺特异性抗原; 丙酮酸激酶

Keywords:

prostatic cancer;  prostate specific antigen;  pyruvate kinase

分类号:

R737.25

DOI:

-

文献标志码:

A

摘要:

目的：比较TuM2-PK，tPSA，fPSA/tPSA和PSAD在PSA灰区对前列腺癌的诊断价值。方法：选取tPSA在4～10 ng/mL的前列腺癌（PCa）、良性前列腺癌增生（BPH）及前列腺炎老年患者共252例，测其血中TuM2-PK，tPSA和fPSA，计算fPSA/tPSA比值；经直肠B超测前列腺体积，计算tPSA与前列腺体积之比，得到PSAD。用SPSS19.0分析TuM2-PK，tPSA，fPSA/tPSA和PSAD在PSA灰区对PCa的诊断价值。结果：PCa组的TuM2-PK，fPSA/tPSA和PSAD较比前列腺炎老年组及BPH组均有显著变化(P<0.05)；3组间的tPSA没有显著差异(P>0.05)。TuM2-PK AUC(0.948)>PSAD AUC(0.801)> fPSA/tPSA AUC (0.610)> tPSA AUC (0.499)。当TuM2-PK，tPSA，fPSA/tPSA和PSAD最佳临界值分别取24.30 U/mL、6.60 ng/mL、0.16和0.15 ng/mL/cm³时，诊断PCa的敏感性和特异性分别为88.9%和92.1%，72.2%和44.9%，80.5%和60.2%，83.3%和71.8%。结论：在PSA灰区，TuM2-PK、fPSA/tPSA、PSAD均能提高PCa诊断的敏感性和特异性，且TuM2-PK比fPSA/tPSA和PSAD对于PCa的诊断具有更高的准确性。

Abstract:

Objective: To explore diagnostic significance of TuM2-PK, tPSA, fPSA/tPSA and PSAD for prostate cancer in PSA gray area. Methods: Two hundred and fifty-two cases with prostatic cancer (PCa), benign prostatic hyperplasia (BPH) and prostatitis whose tPSA levels were between 4 ng/mL and 10 ng/mL were chosen. Plasmatic TuM2-PK and serum fPSA, tPSA were examined. Prostate volume was determined by transrectal ultrasound. PSAD and fPSA/tPSA were calculated. The diagnostic significance of TuM2-PK, tPSA, fPSA/tPSA and PSAD for PCa in PSA gray area were analyzed using SPSS19.0. Results: Compared with BPH group and elderly prostatitis group, TuM2-PK, fPSA/tPSA and PSAD in PCa group were significantly changed (P<0.05); There was no significant difference in tPSA among the three groups. The AUC of these indexes in descending order was TuM2-PK, PSAD, fPSA/tPSA, and tPSA． While the cutoffs of TuM2-PK, tPSA, fPSA/tPSA and PSAD were 24.30 U/mL, 6.60 ng/mL, 0.16 and 0.15 ng/mL/cm³, the sensitivity and specificity of diagnosed PCa were 88.9% and 92.1%，72.2% and 44.9%，80.5% and 60.2%，83.3% and 71.8%, respectively. Conclusion: TuM2-PK, fPSA/tPSA and PSAD can increase sensitivity and specificity inthediagnosis of PCa in PSA gray area. And compared with fPSA/tPSA and PSAD, TuM2-PK is more accurate in diagnosing PCa.

?

参考文献/References:

[1] 丁茗敏. 应用血清PSA进行前列腺癌筛查的意义[J]. 中国疗养医学, 2011,20(2):160

[2] Greene K L, Albertsen P C, Babaian R J, et al. Prostate specific antigen best practice statement: 2009 update[J]. J Urol, 2013,189(1 Suppl):S2

[3] 杨娜, 杨琳, 刘禄, 等. 探讨tPSA,fPSA,f/tPSA和PSAD对PSA灰区前列腺癌的诊断价值[J]. 临床医药实践, 2014,23(1):14

[4] Amirrasouli H, Kazerouni F, Sanadizade M, et al. Accurate cut-off point for free to total prostate-specific antigen ratio used to improve differentiation of prostate cancer from benign prostate hyperplasia in Iranian population[J]. Urol J, 2010,7(2):99

[5] 范本, 齐范, 李文泽, 等. 湖南地区不同年龄、不同前列腺体积与血清中PSA及fPSA水平的相关性研究[J]. 实用预防医学, 2011,18(11):2034

[6] Li J, Yang Z, Zou Q, et al. PKM2 and ACVR 1C are prognostic markers for poor prognosis of gallbladder cancer[J]. Clin Transl Oncol, 2014,16(2):200

[7] Fatela-Cantillo D, Fernandez-Suarez A, Moreno M A, et al. Prognostic value of plasmatic tumor M2 pyruvate kinase and carcinoembryonic antigen in the survival of colorectal cancer patients[J]. Tumour Biol, 2012,33(3):825

[8] Siegel R L, Miller K D, Jemal A. Cancer statistics, 2015[J]. CA Cancer J Clin, 2015,65(1):5

[9] Liu Z Y, Sun Y H, Xu C L, et al. Age-specific PSA reference ranges in Chinese men without prostate cancer[J]. Asian J Androl, 2009,11(1):100

[10] 马志远, 赵林海, 王阳, 等. PSA密度对TPSA灰区前列腺癌的诊断意义[J]. 临床泌尿外科杂志, 2011,26(2):132 .

[11] 贺乐乐, 魏伟, 杨进益. PSA及其相关指数对前列腺癌诊断价值的研究进展[J]. 现代泌尿生殖肿瘤杂志, 2015,7(3):190

[12] Mazurek S. Pyruvate kinase type M2: a key regulator of the metabolic budget system in tumor cells[J]. Int J Biochem Cell Biol, 2011,43(7):969

[13] Chaneton B, Gottlieb E. Rocking cell metabolism: revised functions of the key glycolytic regulator PKM2 in cancer[J]. Trends Biochem Sci, 2012,37(8):309

[14] Morgan H P, O’Reilly F J, Wear M A, et al. M2 pyruvate kinase provides a mechanism for nutrient sensing and regulation of cell proliferation[J]. Proc Natl Acad Sci U S A, 2013,110(15):5881

[15] Gui D Y, Lewis C A, Vander H M . Allosteric regulation of PKM2 allows cellular adaptation to different physiological states[J]. Sci Signal, 2013,6(263):1290

[16] Gao X, Wang H, Yang J J, et al. Pyruvate kinase M2 regulates gene transcription by acting as a protein kinase[J]. Mol Cell, 2012,45(5):598

[17] Feng C, Gao Y, Wang C, et al. Aberrant overexpression of pyruvate kinase M2 is associated with aggressive tumor features and the BRAF mutation in papillary thyroid cancer[J]. J Clin Endocrinol Metab, 2013,98(9):E1524

[18] 刘东林. 特拉唑嗪联合松花粉治疗慢性前列腺炎临床观察[J]. 山西医药杂志, 2014,43(19):2320

[19] Moller-Nielsen C, Sell A. Granulomatous prostatitis. Differential diagnosis from cancer of the prostate[J]. Ugeskr Laeger, 1983,145(13):994

?

相似文献/References:

[1]魏强,齐灿,罗飞,等.转移性去势抵抗性前列腺癌患者多西他赛化疗的预后分析[J].天津医科大学学报,2013,19(05):390.
[2]杨帮东,姜行康,齐 灿,等.尿液中PCA3评分对前列腺癌早期诊断的临床意义[J].天津医科大学学报,2013,19(06):487.
　YANG Bang-dong,JIANG Xing-kang,QI Can,et al.Clinical significance of urinary PCA3 score to diagnose prostate cancer[J].Journal of Tianjin Medical University,2013,19(02):487.
[3]刘利维,刘春雨. MicroRNAs 与前列腺癌的表观遗传学研究进展[J].天津医科大学学报,2014,20(01):74.
[4]王 超,余泉峰,徐 勇,等.经直肠超声造影诊断前列腺癌的临床分析[J].天津医科大学学报,2014,20(05):375.
　WANG Chao,YU Quan-feng,XU Yong,et al.Clinical analysis of contrast-enhanced transrectal ultrasonography for the diagnosis of prostate cancer[J].Journal of Tianjin Medical University,2014,20(02):375.
[5]张晓会,张志宏,徐 勇,等.合并症对局限性或局部晚期前列腺癌患者早期生存的影响[J].天津医科大学学报,2014,20(05):379.
　ZHANG Xiao-hui,ZHANG Zhi-hong,XU Yong,et al. Influence of complications on early survival of patients with localized or locally advanced prostate cancer[J].Journal of Tianjin Medical University,2014,20(02):379.
[6]盛 镔,张 蒙,马鹏德,等.核糖体蛋白L37在前列腺癌中的表达及临床意义[J].天津医科大学学报,2015,21(05):401.
　SHENG Bin,ZHANG Meng,MA Peng-de,et al.Expression of ribosomal protein L37 in prostate cancer and its clinical significance[J].Journal of Tianjin Medical University,2015,21(02):401.
[7]李 江,张恩龙,赵 阳,等.前列腺癌靶向磁共振成像和光热治疗的实验研究[J].天津医科大学学报,2017,23(02):93.
　LI Jiang,ZHANG En-long,ZHAO Yang,et al.?Experimental research of targeted magnetic resonance imaging and photo thermal therapy for prostate cancer [J].Journal of Tianjin Medical University,2017,23(02):93.
[8]张一然,潘盼,连振鹏,等.磁共振扫描对经直肠超声引导前列腺穿刺活检的影响[J].天津医科大学学报,2017,23(02):99.
　ZHANG Yi-ran,PAN Pan,LIAN Zhen-peng,et al.Effect of magnetic resonance imaging scan on the?transrectal ultrasound?prostate biopsy[J].Journal of Tianjin Medical University,2017,23(02):99.
[9]薄志强,孙桂江,王 丽,等.CtBP2异常表达对前列腺癌PC3细胞增殖效应影响的研究[J].天津医科大学学报,2017,23(02):103.
　BO Zhi-qiang,SUNGui-jiang,WANG Li,et al.Effect of abnormal expression of CtBP2 on the proliferation of prostate cancer cell line PC3[J].Journal of Tianjin Medical University,2017,23(02):103.
[10]徐庆祝,牛远杰.Gleason 10分前列腺癌患者临床特点分析[J].天津医科大学学报,2017,23(04):361.
　XU Qing-zhu,NIU Yuan-jie.Clinical and pathological research of prostate cancer with Gleason score 10[J].Journal of Tianjin Medical University,2017,23(02):361.

备注/Memo

备注/Memo:

基金项目 国家自然科学基金资助项目(81201653)；天津市卫生局课题基金资助(2011KZ77)
作者简介 管明秀(1982-)，女，临床检验初级技师，硕士在读，研究方向：临床检验诊断学；通信作者：周云丽，E-mail：zhouyunli@tjmuch.com。

常用功能

更新日期/Last Update: 2016-03-23